Journal article icon

Journal article

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage

Abstract:
Objectives The significance of antibodies directed against activated factor X (FXa) and thrombin (Thr) in patients with SLE and/or antiphospholipid syndrome (APS) is unknown. FXa and Thr are coregulated by antithrombin (AT) and activate complement. Therefore, we studied the ability of anti activated factor X (aFXa) and/or anti-(a)Thr IgG from patients with SLE±APS to modulate complement activation.Methods Patients with SLE±APS were selected on the basis of known aThr and/or aFXa IgG positivity, and the effects of affinity-purified aFXa/aThr IgG on FXa and Thr-mediated C3 and C5 activation were measured ±AT. Structural analyses of FXa and Thr and AT–FXa and AT–Thr complexes were analysed in conjunction with the in vitro ability of AT to regulate aFXa–FXa and aThr–Thr-mediated C3/C5 activation.Results Using affinity-purified IgG from n=14 patients, we found that aThr IgG increased Thr-mediated activation of C3 and C5, while aFXa IgG did not increase C3 or C5 activation. Structural analysis identified potential epitopes and predicted a higher likelihood of steric hindrance of AT on FXa by aFXa IgG compared with the AT–Thr–aThr IgG complex that was confirmed by in vitro studies. Longitudinal analysis of 58 patients with SLE (±APS) did not find a significant association between positivity for aFXa or aTHr IgG and C3 levels or disease activity, although there was a trend for patients positive for aFXa IgG alone or both aFXa and aThr IgG to have lower levels of C3 compared with aThr IgG alone during clinical visits.Conclusions We propose a novel method of complement regulation in patients with SLE±APS whereby aFXa and aThr IgG may have differential effects on complement activation
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1136/lupus-2022-000738
Publication website:
https://discovery.ucl.ac.uk/10154699/1/e000738.full.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0002-2898-4457
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-2982-1756
More by this author
Role:
Author
ORCID:
0000-0001-8804-0493


More from this funder
Funder identifier:
10.13039/501100000265
Grant:
MR/P017371/1
More from this funder
Funder identifier:
https://ror.org/05q2q3076
More from this funder
Funder identifier:
10.13039/501100012041
More from this funder
Funder identifier:
10.13039/501100000825


Publisher:
BMJ Publishing Group
Journal:
Lupus Science & Medicine More from this journal
Volume:
9
Issue:
1
Pages:
e000738-e000738
Publication date:
2022-08-25
Acceptance date:
2022-08-08
DOI:
EISSN:
2053-8790
ISSN:
2053-8790


Language:
English
Keywords:
Pubs id:
1276507
Local pid:
pubs:1276507
Source identifiers:
W4293239166
Deposit date:
2026-04-28
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP